- Recent Funding
- Founders
- Krishna Polu
About Krishna
Krishna Polu is the Co-Founder, President, and CEO of R1 Therapeutics, a company focused on developing treatments for kidney disease patients. He launched R1 Therapeutics in partnership with Alebund Pharmaceuticals, securing significant Series A financing. Polu has expressed excitement about the company's approach to addressing hyperphosphatemia, a challenge in managing chronic kidney disease patients. He believes AP306, their lead candidate, offers a new method for treatment with potential for superior efficacy.
Strengths: founder archetype
one sourced signal · hover a cell for it, click for the source
Why domain operator
Krishna Polu co-founded R1 Therapeutics and serves as its President and CEO, indicating direct operational leadership. His statements reflect a deep understanding of the challenges in kidney care and the specific mechanism of action of their lead product, AP306.
The signals behind it 2
Network
Background
1
- Role Co-Founder, President and CEO
P
Timeline, line by line 2
C
PIn their words
2
- “We are excited to be launching R1 Therapeutics in partnership with Alebund and with support from a strong, experienced syndicate including DaVita and U.S. Renal Care, recognized global providers transforming kidney care. This backing, plus a differentiated clinical-stage asset, positions us to address one of the most persistent challenges in managing patients with chronic kidney disease.”On the launch of R1 Therapeutics and its mission to address kidney disease. · Mar 17, 2026P
- “Samsara brings a rare combination of scientific depth and a track record of investing in kidney companies across the private and public markets. Their decision to join ahead of the Phase 2b readout is a strong endorsement of our novel approach to addressing hyperphosphatemia. With our global trial underway, their support, alongside that of our existing syndicate, further strengthens our ability to generate the clinical data needed to bring AP306 to patients.”On Samsara BioCapital joining the Series A financing and its implications for AP306 development. · Sep 30, 2026
P
Interviews and coverage
4
- R1 Therapeutics debuts with $77.5m to tackle kidney diseaseBioXconomy · Mar 17, 2026
B - New renal disease biotech R1 Therapeutics nabs $77.5M for Phase 2bEndpoints News · Mar 17, 2026
E - R1 Therapeutics launches with $77.5m to advance hyperphosphatemia treatmentPharmaTimes · Mar 17, 2026P
- R1 Therapeutics Expands Series A To $80.5 Million To Advance AP306Pulse 2.0 · Sep 30, 2026P
How this is researched
Researched from public pages: press, interviews, the company's site and the founder's own posts. Each source logo links the page that states the row; anything we couldn't source is left out. The archetype is our reading of that record, from a fixed set so founders can be compared. Updated Oct 14, 2026.
The week's top funded startups and market insights, in your inbox every Monday.
Unsubscribe anytime · privacy